Global Pharmaceutical and Analytical Sciences, Abbott Laboratories, IL 60064, USA.
Mol Pharm. 2010 Oct 4;7(5):1458-65. doi: 10.1021/mp100114a. Epub 2010 Aug 12.
A biphasic in vitro test method was used to examine release profiles of a poorly soluble model drug, celecoxib (CEB), from its immediate release formulations. Three formulations of CEB were investigated in this study, including a commercial Celebrex capsule, a solution formulation (containing cosolvent and surfactant) and a supersaturatable self-emulsifying drug delivery system (S-SEDDS). The biphasic test system consisted of an aqueous buffer and a water-immiscible organic solvent (e.g., octanol) with the use of both USP II and IV apparatuses. The aqueous phase provided a nonsink dissolution medium for CEB, while the octanol phase acted as a sink for CEB partitioning. For comparison, CEB concentration-time profiles of these formulations in the aqueous medium under either a sink condition or a nonsink condition were also explored. CEB release profiles of these formulations observed in the aqueous medium from either the sink condition test, the nonsink condition test, or the biphasic test have little relevance to the pharmacokinetic observations (e.g., AUC, C(max)) in human subjects. In contrast, a rank order correlation among the three CEB formulations is obtained between the in vitro AUC values of CEB from the octanol phase up to t = 2 h and the in vivo mean AUC (or C(max)) values. As the biphasic test permits a rapid removal of drug from the aqueous phase by partitioning into the organic phase, the amount of drug in the organic phase represents the amount of drug accumulated in systemic circulation in vivo. This hypothesis provides the scientific rationale for the rank order relationship among these CEB formulations between their CEB concentrations in the organic phase and the relative AUC or C(max). In addition, the biphasic test method permits differentiation and discrimination of key attributes among the three different CEB formulations. This work demonstrates that the biphasic in vitro test method appears to be useful as a tool in evaluating performance of formulations of poorly water-soluble drugs and to provide potential for establishing an in vitro-in vivo relationship.
采用双相体外试验方法考察了难溶性模型药物塞来昔布(CEB)从其即释制剂中的释放特征。本研究考察了三种 CEB 制剂,包括市售 Celebrex 胶囊、溶液制剂(含有助溶剂和表面活性剂)和超饱和自乳化药物传递系统(S-SEDDS)。双相试验系统由水缓冲液和水不溶性有机溶剂(如辛醇)组成,同时使用 USP II 和 IV 仪器。水相为 CEB 提供了非溶出度溶解介质,而辛醇相则为 CEB 分配的溶出度介质。为了比较,还考察了这些制剂在水相中的 CEB 浓度-时间曲线,这些制剂在水相中的条件分别为溶出度条件或非溶出度条件。从溶出度条件试验、非溶出度条件试验或双相试验中观察到的这些制剂在水相中的 CEB 释放曲线与人体观察到的药代动力学参数(如 AUC、C(max))相关性不大。相比之下,在辛醇相中至 t = 2 h 的 CEB 的体外 AUC 值与体内平均 AUC(或 C(max))值之间,三种 CEB 制剂之间存在等级相关性。由于双相试验通过分配到有机相而迅速将药物从水相除去,因此有机相中的药物量代表了药物在体内循环系统中的积累量。该假设为这些 CEB 制剂在有机相中的 CEB 浓度与其相对 AUC 或 C(max)之间的等级关系提供了科学依据。此外,双相试验方法允许区分和鉴别三种不同 CEB 制剂之间的关键属性。这项工作表明,双相体外试验方法似乎可作为评估难溶性药物制剂性能的工具,并为建立体外-体内相关性提供了潜力。